Showing results (11-20 of 58) with videos related to
Sort By:
Pageof 6
Life Sciences|October 3, 2013
Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?William E Fantegrossi, Jeffery H Moran, Anna Radominska-Pandya, et al.Molecular Interventions|March 29, 2011
Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?Kathryn A Seely, Paul L Prather, Laura P James, et al.Toxicological Sciences : an Official Journal of the Society of Toxicology|February 24, 2022
Metabolites of Synthetic Cannabinoid 5F-MDMB-PINACA Retain Affinity, Act as High Efficacy Agonists and Exhibit Atypical Pharmacodynamic Properties at CB1 ReceptorsChristian V Cabanlong, Lauren N Russell, William E Fantegrossi, et al.Anti-Cancer Agents in Medicinal Chemistry|May 16, 2012
Unifying mechanisms of action of the anticancer activities of triterpenoids and synthetic analogsStephen H Safe, Paul L Prather, Lisa K Brents, et al.Toxicology and Applied Pharmacology|June 16, 2018
The tamoxifen derivative ridaifen-B is a high affinity selective CB<sub>2</sub> receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effectsLirit N Franks, Benjamin M Ford, Toshifumi Fujiwara, et al.Toxicology and Applied Pharmacology|March 30, 2013
Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptorsMaheswari Rajasekaran, Lisa K Brents, Lirit N Franks, et al.The Journal of Pharmacology and Experimental Therapeutics|May 20, 2005
The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptorsJennifer L Shoemaker, Biny K Joseph, Michael B Ruckle, et al.The Journal of Pharmacology and Experimental Therapeutics|June 27, 2013
Differential drug-drug interactions of the synthetic Cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapyLisa K Brents, Sarah M Zimmerman, Amanda R Saffell, et al.Journal of Neurochemistry|January 24, 2007
The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onsetJennifer L Shoemaker, Kathryn A Seely, Ronald L Reed, et al.International Journal of Molecular Sciences|March 25, 2022
Non-Canonical Cannabinoid Receptors with Distinct Binding and Signaling Properties in Prostate and Other Cancer Cell Types Mediate Cell DeathAmal M Shoeib, Lance N Benson, Shengyu Mu, et al.Pageof 6